FDA’s pediatric anti-infective guidance encourages efficacy extrapolation, adolescent inclusion in adult pivotal trials

FDA’s latest pediatric guidance outlines what’s needed to extrapolate efficacy of anti-infective drugs from adults to children, and sends a clear message that adult trials should include patients aged 12 and up whenever possible.

Because anti-infectives

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE